Altimmune (ALT) Competitors

In the previous week, Pharvaris had 24 more articles in the media than Altimmune. MarketBeat recorded 25 mentions for Pharvaris and 1 mentions for Altimmune. Pharvaris' average media sentiment score of 0.53 beat Altimmune's score of -0.71 indicating that Pharvaris is being referred to more favorably in the news media.

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Pharvaris' return on equity.

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Altimmune presently has a consensus target price of $14.33, indicating a potential upside of 341.03%. Pharvaris has a consensus target price of $59.87, indicating a potential upside of 64.60%. Given Altimmune's higher probable upside, research analysts plainly believe Altimmune is more favorable than Pharvaris.

Altimmune has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, suggesting that its share price is 333% less volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to Altimmune's net margin of -214,860.98%. Beam Therapeutics' return on equity of -30.71% beat Altimmune's return on equity.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Altimmune. Beam Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

In the previous week, Beam Therapeutics had 4 more articles in the media than Altimmune. MarketBeat recorded 5 mentions for Beam Therapeutics and 1 mentions for Altimmune. Beam Therapeutics' average media sentiment score of 0.50 beat Altimmune's score of -0.71 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Altimmune presently has a consensus target price of $14.33, indicating a potential upside of 341.03%. Beam Therapeutics has a consensus target price of $49.00, indicating a potential upside of 96.39%. Given Altimmune's higher probable upside, research analysts clearly believe Altimmune is more favorable than Beam Therapeutics.

Altimmune has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market.

Precigen presently has a consensus price target of $14.50, suggesting a potential upside of 86.38%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 341.03%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than Precigen.

Precigen has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Precigen has a net margin of -183.98% compared to Altimmune's net margin of -214,860.98%. Precigen's return on equity of 423.75% beat Altimmune's return on equity.

Altimmune has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

In the previous week, Precigen had 5 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Precigen and 1 mentions for Altimmune. Precigen's average media sentiment score of 0.85 beat Altimmune's score of -0.71 indicating that Precigen is being referred to more favorably in the media.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 41.4% of Precigen shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Altimmune has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Viridian Therapeutics has a net margin of -505.86% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Viridian Therapeutics' return on equity.

78.1% of Altimmune shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Altimmune presently has a consensus price target of $14.33, indicating a potential upside of 341.03%. Viridian Therapeutics has a consensus price target of $38.54, indicating a potential upside of 75.17%. Given Altimmune's higher probable upside, analysts clearly believe Altimmune is more favorable than Viridian Therapeutics.

In the previous week, Altimmune and Altimmune both had 1 articles in the media. Viridian Therapeutics' average media sentiment score of 1.77 beat Altimmune's score of -0.71 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Altimmune has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.